Trial Profile
Treatment of Cervical Spinal Cord Injury with Imatinib – a safety and feasibility study
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Spinal cord injuries
- Focus Pharmacokinetics
- 05 Mar 2018 Planned End Date changed from 1 Dec 2015 to 1 Dec 2021.
- 05 Mar 2018 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2020.
- 20 Feb 2015 New trial record